4749 Glycemic control A1c reductions resulting from treatment with SGLT2-I with or without background therapy of MET in randomized trials are summarized in Table 2
Controls showed the expected 18% femoral BMD loss by week 12
By modulating GLP-1R signaling, it is possible to influence the survival of alloimmune grafts and the growth of tumors, providing new strategies for immune regulation and cancer therapy [16]
Importantly, increased levels of P4 found in the LC-treated ewes at Day 8 may be related to the increased LBF that could positively influence the secretory function of CLs as previously reported in buffaloes [34, 89], cows [36, 90], goats [37, 47], and sheep [46]
1 Detailed results from both trials will be presented at future medical meetings and published in peer-reviewed journals
Sweeten (optional): If you prefer a sweeter taste, you can add a small amount of honey or a pinch of stevia